Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07424027 · ClinicalTrials.gov registry record · NA

Central Vein Sign in Multiple Sclerosis Extension Study

A NA study of Multiple Sclerosis, sponsored by The Cleveland Clinic.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
3
Study locations

NCT07424027 is a NA study of Multiple Sclerosis that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 40 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07424027, a NA study of Multiple Sclerosis, is actively recruiting participants, sponsored by The Cleveland Clinic.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
3
Study locations

Study Summary

Multiple sclerosis (MS) is a common disease of the central nervous system that affects almost 1 million people in the United States. However, diagnosing MS can be difficult and often leads to misdiagnosis. More sensitive and specific biomarkers are needed to help with the diagnosis, prognosis, and evaluation of treatment response for MS. The central vein sign (CVS) and the paramagnetic rim lesion (PRL) are two biomarkers that have shown promise in improving diagnostic accuracy for MS. The goal of this study is to provide pilot information on the long-term performance of the CVS and PRL to help diagnose and follow people with MS. The study will follow 40 participants over 48 months to determine if the CVS and PRL help make a diagnosis of MS and how they can be used to follow people with MS. The study will also examine how PRL and CVS change over 48 months. The results of this pilot study will inform the development of a grant application to extend 5-year follow-up for all 420 participants of the CAVS-MS study. The study will use high-resolution T2\*-weighted MRI to detect the CVS and PRLs. An MRI of the brain with contrast will be used to examine CVS, PRL and longitudinal analysis of lesions that slowly grow over time (slowly expanding lesions \[SELs\]). The results of this study have the potential to improve the accuracy of diagnosing and treating MS.

Conditions Studied

Multiple Sclerosis

Interventions

  • DIAGNOSTIC_TEST MRI Contrast

Study Locations (3)

California

  • Cedars-Sinai Medical Center - Los Angeles

Ohio

  • Cleveland Clinic Foundation - Cleveland

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-10-07
Est. Completion 2027-12-31
Phase NA

Sponsor

The Cleveland Clinic

688 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07424027

The ClinicalTrials.gov registry entry for NCT07424027 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which MRI Contrast is the first listed.

NCT07424027 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Ohio, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07424027 about?

NCT07424027 is a clinical study titled "Central Vein Sign in Multiple Sclerosis Extension Study". Multiple sclerosis (MS) is a common disease of the central nervous system that affects almost 1 million people in the United States. However, diagnosing MS can be difficult and often leads to misdiagnosis. More sensitive and specific biomarkers are needed to help with the diagnosis, prognosis, and e...

What is the current status of trial NCT07424027?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-10-07. Estimated completion is 2027-12-31.

What conditions does trial NCT07424027 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT07424027?

The interventions under investigation include: MRI Contrast (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07424027?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07424027 being conducted?

This trial has 3 study locations across California, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.